This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. ZD1839 was developed as an inhibitor of the epidermal growth factor receptor tyrosine kinase. Key features of ZD1839 are its extremely potent and selective inhibitor of EGFR tyrosine kinase, showing, reversible inhibition of tumor cell growth. Ex vivo pharmacology studies have show dose-dependent reduction in the biomarker of EGF signaling c-fos mRNA. It appears that ZD1839 may be well-tolerated, orally effective, anti-tumor agent.
Showing the most recent 10 out of 1085 publications